-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Wedbush Comments on TCR2 Therapeutics Inc.'s Q3 2022 Earnings (NASDAQ:TCRR)
Wedbush Comments on TCR2 Therapeutics Inc.'s Q3 2022 Earnings (NASDAQ:TCRR)
TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) – Stock analysts at Wedbush cut their Q3 2022 earnings estimates for shares of TCR2 Therapeutics in a research note issued to investors on Wednesday, September 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for TCR2 Therapeutics' current full-year earnings is ($3.19) per share. Wedbush also issued estimates for TCR2 Therapeutics' Q4 2022 earnings at ($0.37) EPS and FY2022 earnings at ($2.76) EPS.
Get TCR2 Therapeutics alerts:Several other research analysts have also commented on TCRR. Roth Capital restated a "buy" rating on shares of TCR2 Therapeutics in a report on Monday, August 8th. Truist Financial cut their price target on shares of TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.
TCR2 Therapeutics Trading Up 4.7 %
NASDAQ:TCRR opened at $1.80 on Monday. The firm has a market cap of $69.49 million, a price-to-earnings ratio of -0.60 and a beta of 1.79. TCR2 Therapeutics has a 12-month low of $1.60 and a 12-month high of $8.82. The company's 50-day moving average is $2.78 and its two-hundred day moving average is $2.69.TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.05).
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the 1st quarter. GSA Capital Partners LLP now owns 158,593 shares of the company's stock valued at $438,000 after acquiring an additional 84,191 shares in the last quarter. Marquette Asset Management LLC increased its position in TCR2 Therapeutics by 20.7% in the 2nd quarter. Marquette Asset Management LLC now owns 40,163 shares of the company's stock worth $116,000 after buying an additional 6,901 shares during the period. Jane Street Group LLC bought a new position in TCR2 Therapeutics in the 2nd quarter worth approximately $38,000. Orion Portfolio Solutions LLC bought a new stake in shares of TCR2 Therapeutics during the second quarter valued at approximately $39,000. Finally, Acadian Asset Management LLC increased its position in shares of TCR2 Therapeutics by 3,250.7% during the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company's stock valued at $1,322,000 after purchasing an additional 465,207 shares during the period. 64.56% of the stock is owned by institutional investors and hedge funds.
About TCR2 Therapeutics
(Get Rating)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
Further Reading
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
TCR2 Therapeutics Inc. (NASDAQ:TCRR – Get Rating) – Stock analysts at Wedbush cut their Q3 2022 earnings estimates for shares of TCR2 Therapeutics in a research note issued to investors on Wednesday, September 28th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their previous estimate of ($0.36). The consensus estimate for TCR2 Therapeutics' current full-year earnings is ($3.19) per share. Wedbush also issued estimates for TCR2 Therapeutics' Q4 2022 earnings at ($0.37) EPS and FY2022 earnings at ($2.76) EPS.
TCR2治疗公司(纳斯达克:TCRR-GET评级)--韦德布什的股票分析师在9月28日星期三发给投资者的一份研究报告中下调了他们对TCR2治疗公司股票2022年第三季度的收益预期。韦德布什分析师D.尼伦加滕现在预计,该公司本季度每股收益将为0.82美元,低于此前预测的0.36美元。对TCR2治疗公司目前全年收益的普遍估计为每股3.19美元。韦德布什还发布了对TCR2治疗公司2022年第四季度每股收益(0.37美元)和2022财年每股收益(2.76美元)的估计。
Several other research analysts have also commented on TCRR. Roth Capital restated a "buy" rating on shares of TCR2 Therapeutics in a report on Monday, August 8th. Truist Financial cut their price target on shares of TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.71.
其他几位研究分析师也对TCRR发表了评论。Roth Capital在8月8日星期一的一份报告中重申了对TCR2治疗公司股票的“买入”评级。Truist Financial在8月23日星期二的一份报告中将TCR2治疗公司的股票目标价下调至18.00美元。两名研究分析师对该股的评级为持有,四名分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的平均评级为“适度买入”,共识目标价为16.71美元。
TCR2 Therapeutics Trading Up 4.7 %
TCR2治疗公司股价上涨4.7%
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.05).
TCR2治疗公司(纳斯达克代码:TCRR-GET Rating)上一次公布季度收益是在8月8日星期一。该公司公布本季度每股收益为0.82美元,低于分析师普遍预期的0.77美元和0.05美元。
Institutional Inflows and Outflows
机构资金流入和流出
Hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the 1st quarter. GSA Capital Partners LLP now owns 158,593 shares of the company's stock valued at $438,000 after acquiring an additional 84,191 shares in the last quarter. Marquette Asset Management LLC increased its position in TCR2 Therapeutics by 20.7% in the 2nd quarter. Marquette Asset Management LLC now owns 40,163 shares of the company's stock worth $116,000 after buying an additional 6,901 shares during the period. Jane Street Group LLC bought a new position in TCR2 Therapeutics in the 2nd quarter worth approximately $38,000. Orion Portfolio Solutions LLC bought a new stake in shares of TCR2 Therapeutics during the second quarter valued at approximately $39,000. Finally, Acadian Asset Management LLC increased its position in shares of TCR2 Therapeutics by 3,250.7% during the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company's stock valued at $1,322,000 after purchasing an additional 465,207 shares during the period. 64.56% of the stock is owned by institutional investors and hedge funds.
对冲基金最近买卖了该公司的股票。第一季度,GSA Capital Partners LLP在TCR2治疗公司的持股增加了113.2%。GSA Capital Partners LLP在上个季度增持了84,191股后,现在拥有158,593股该公司股票,价值438,000美元。Marquette Asset Management LLC在第二季度将其在TCR2治疗公司的头寸增加了20.7%。Marquette Asset Management LLC在此期间又购买了6901股,现在拥有40,163股该公司股票,价值11.6万美元。简街集团在第二季度购买了TCR2治疗公司的一个新头寸,价值约3.8万美元。Orion Portfolio Solutions LLC在第二季度购买了TCR2治疗公司的新股份,价值约3.9万美元。最后,Acadian Asset Management LLC在第一季度将其在TCR2治疗公司的股份增加了3,250.7%。Acadian Asset Management LLC在此期间又购买了465,207股,目前拥有479,518股该公司股票,价值1,322,000美元。64.56%的股票由机构投资者和对冲基金持有。
About TCR2 Therapeutics
关于TCR2治疗公司
(Get Rating)
(获取评级)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
TCR2治疗公司是一家临床阶段免疫治疗公司,专注于为癌症患者开发新型T细胞受体(TCR)疗法。该公司的主要候选产品包括Gavo-cel,一种针对Mesothelin阳性实体肿瘤的单一TCR融合结构T细胞(TRUC-T细胞),正在进行I/II期临床试验,用于治疗非小细胞肺癌(NSCLC)、卵巢癌、恶性胸膜/腹膜间皮瘤和胆管癌。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免费获取StockNews.com关于TCR2治疗的研究报告(TCRR)
- 阿彻·丹尼尔斯·米德兰:49年增长的红利英雄
- 全自动拖拉机会让迪尔成为农业领域的特斯拉吗?
- 麦格纳国际是您的汽车和电动汽车一站式库存
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat:回顾一周9/26-9/30
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《TCR2治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对TCR2治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧